Leadership
Chief Executive Officer, USA
Daniel Dietz
As Chief Executive Officer of Longevity Labs, Inc. in the United States, Daniel Dietz has applied his expertise in business formation, development, and investor relations to launch the company’s U.S. headquarters in Denver, Colorado in 2020, and its successful introduction of Longevity Labs’ flagship product, spermidineLIFE®.
Managing all aspects of the company’s US operations, Dietz leads the company’s teams and business partners to bring their first-of-its-kind natural spermidine supplementation product to market. Leveraging his unique combination of business, marketing, and legal talents, Dietz helped grow spermidineLIFE® sales from zero to $2.8M in 18 short months.
Before joining Longevity Labs, Dietz successfully launched ventures in real estate, retail, cannabis, dietary supplements, and technology. Dietz received a BA in Business Management from Anderson University, with an MBA and a JD from the University of New Mexico.
Always up for new challenges and experiences, Dietz enjoys trips to the Colorado mountains, live music, and off-the-beaten path restaurants.
Director of Applied Science, USA
Don Moxley
Don Moxley is Director of Applied Science and Brand Development at Longevity Labs Inc. in the United States. Dedicated to helping people live vibrant, fulfilling lives at all ages, Moxley draws upon his career as an athlete, a sports scientist, and an instructor to lead and educate on the science of autophagy and longevity.
Focusing his work on the cell renewal benefits of spermidine supplementation, Don is a regarded longevity science leader known for making the complex simple.
Whether it’s a one-on-one podcast interview heard by thousands, a presentation of research on spermidine to a wellness conference or plain talk to people who want to live their best lives as they grow older, Don makes the science of adding more life to our years immediately understandable.
Throughout his life and career, Moxley has applied science to enhancing well-being. A former captain and Big 10 Championship winner with the Ohio State University wrestling team, Don served as the university’s first sport scientist. By giving athletes the ability to track their progress in strength, cardiovascular and resilience training, he helped the wrestling team win a national title and three Big 10 Championships. He has helped athletes achieve two Olympic metals, four World Championships, seven National Championships and 23 All-Americans.
A resident of Granville Ohio, Moxley has been married to his wife Laura since 1990. When he’s not sharing knowledge about spermidine, cell renewal or longevity, he’s studying human performance.
Co-Founder & Chief Executive Officer, Austria
Vedran Bijelac
Vedran Bijelac is Chief Executive Officer of Longevity Labs GmbH at the company’s Graz, Austria headquarters. Dedicated to advancing the company he co-founded with Herbert Pock and Gerald Sitte in 2016, Bijelac directs and oversees Longevity Labs’ international organization and production facility.
Building on Longevity Labs’ ongoing work with academic, scientific and industrial organizations, Bijelac cultivates new scientific and business partnerships in Europe and the U.S. Bijelac also supports planning, sales and marketing activities in Europe and the U.S. for the company’s flagship product, the autophagy-inducing supplement spermidineLIFE®.
Before co-founding Longevity Labs, Bijelac served in management positions with several industrial groups in Europe in operations, business management, joint venture and merger and acquisition roles. He obtained his bachelor’s and master’s degrees in business and science from Karl-Franzens-Universität in Graz, Austria, and his MBA from the University of New Mexico Anderson School of Management.
Co-Founder & Managing Director, Austria
Gerald Sitte
Gerald Sitte is Managing Director of Longevity Labs GmbH in Graz, Austria, which he co-founded with Herbert Pock and Vedran Bijelac in 2016. Sitte and his partners laid the groundwork, developed production facilities, and now oversee growth of Longevity Labs and its flagship product, spermidineLIFE®.
A multilingual communicator, he applies his keen sense of intercultural relationship building across industry networks. Sitte’s approaches support Longevity Labs’ creative thinking and cross-functional work ethic, innovative and efficient production methods, and new products.
Before co-founding Longevity Labs, Sitte served as CEO with several industrial companies in Austria, Europe and Russia, managing operations, finance and merger and acquisition activities. He has served as a senior consultant and CEO with Austin Life Science Partners AG in Switzerland and Austria.
With a focus on mechanical engineering and business, Sitte received his MS and his Ph.D. degrees from the Technical University Graz, Graz Austria. He continues to serve as a lecturer in management, finance, economics and controlling, and is an assessor of bachelor and master’s theses, at the university’s applied science campus. In his free time, he enjoys sports and being with family.
Co-Founder, Chief Executive Officer & Managing Director, Austria
Herbert Pock
As Co-Founder, Chief Executive Officer, and Managing Director of Longevity Labs GmbH, Herbert Pock directs the company's business development and partnering, funding, and financial activities. With his co-founders Gerald Sitte and Vedran Bijelac, Pock laid the groundwork for and oversaw company growth to launch its flagship product, spermidineLIFE®.
Pock brings to Longevity Labs two decades of success in operations and financial roles at Austria's industrial, technology, life science, and consulting firms. With expertise in optimizing material flow systems and quality management programs, he frequently advises leaders at other start-up companies. He serves on the board of directors at the Switzerland-Austria-Liechtenstein Chamber of Commerce, a networking and development hub for Switzerland, Austria, Liechtenstein, and central and Eastern Europe.
Pock received his master's degree in Mechanical Engineering and Business Economics from Graz University of Technology, Austria.
Scientific Advisory Board
Elizabeth Yurth, MD
Dr. Yurth is Medical Director of the Boulder Longevity Institute which she co-founded in 2006. The Boulder Longevity Institute specializes in advanced, research-based longevity medicine including treatments such as Bioidentical Hormone Replacement Therapy, Regenerative Orthopedic Procedures, and Regenerative Peptide Therapy, with a result-oriented approach to health optimization. Dr. Yurth is double board-certified in Physical Medicine and Rehabilitation and Anti-Aging/Regenerative Medicine.
As a specialist in Sports, Spine and Regenerative Medicine, she has a Stanford-affiliated Fellowship in Sports and Spine Medicine, and a dual-Fellowship in Anti-Aging and Regenerative Medicine (FAARM) and Anti-Aging, Regenerative and Functional Medicine (FAARFM) through the American Academy of Anti-Aging Medicine (A4M).
Dr. Yurth has been selected as one of the 25 mastermind physician fellows in SSRP (Seeds Scientific Research and Performance) which allows her to stay abreast and teach others in the emerging field of cellular medicine. An active athlete herself, Dr. Yurth has consulted with numerous sports teams including the San Francisco 49ers and the Stanford University women’s basketball and soccer teams. She has served as physician for the San Jose/Cleveland Ballet.
Scientific Advisory Board
Lorenzo Galluzzi, PhD
Dr. Galluzzi is and Italian and French cell biologist who is known for his experimental contributions to the fields of cell death, autophagy, tumor metabolism and tumor immunology. He is one of the most cited young researchers in the world, and one of the most cited doctors in Italy.
Dr. Galluzzi is Assistant Professor of Cell Biology at the Department of Radiation Oncology at Weill Cornell Medical College, New York and Assistant Professor and Adjunct the Department of Dermatology at Yale School of Medicine, New Haven. He is Associate Director of the European Academy for Tumor Immunology (EATI) and a Founding Member of the European Research Institute for Integrated Cellular Pathology (ERI-ICP).
Dr. Galluzzi has provided profound insights into the links between adaptive stress responses in cancer cells and the activation of a clinically relevant tumor-targeting immune response in the context of chemotherapy and radiation therapy. He has published more than 400 scientific articles in more than 100 different international peer-reviewed journals, collaborating with more than 3,000 co-authors. According to Google Scholar, Galluzzi has a h-index of 109, placing him amongst the top-50 Italian scientists working in biomedical sciences.
In addition to his research and dissemination activity, Galluzzi currently operates as Editor-in-Chief of three journals: OncoImmunology (which he co-founded with Dr. Guido Kroemer and Dr. Laurence Zitvogel in 2011), International Review of Cell and Molecular Biology, and Molecular and Cellular Oncology (which he co-founded with Dr. Guido Kroemer in 2013). Galluzzi also serves as Founding Editor for Microbial Cell and Cell Stress, and Associate Editor for Cell Death and Disease and Aging.
Scientific Advisory Board
Stephan Sigrist, PhD
Dr. Sigrist is an Eienstein Professor at the Einstein Foundation and Co-Director of the NeuroCure Cluster of Excellence, Charite University Medicine, Berlin. His areas of research include neurobiology of model organisms, synaptic plasticity, learning and memory processes, aging of synapses, and cognitive brain performance.
Dr. Sigrist is a Professor in Genetics, Institute of Biology, Free University, Berlin. He is Speaker on the study “Scaffolding of Membranes – Mollecular Mechanisms and Cellular Functions” at the Collaborative Research Centre 958, Freie University, Berlin. After post-doctorate research at the Friedrich Miester Laboratory of the Max Planck Society in Tubingen, Germany, he served as Principal Investigator of the Society’s “Neuroplasticity” Independent Junior Research Group in Göttingen. He served as Associate Professor for Experimental Biomedicine and Bio-Imaging, Rudolf Virchow Center of Excellence, Universität Würzburg, Germany.
Scientific Advisory Board
Guido Kroemer, MD, PhD, PU-PH
Dr. Guido Kroemer has made important contributions to medical research through his groundbreaking work in the fields of cell biology and cancer research. He is best known for the discovery that the permeabilization of mitochondrial membranes constitutes a decisive step in programmed cell death. His work has had far reaching implications for the comprehension, detection, and therapeutic manipulation of cellular demise.
Dr. Kroemer is a molecular biologist, immunologist, professor, and director of the European Research Institute for Integrated Cellular Pathology at the Paris Descartes University Faculty of Medicine. He is director of the Apoptosis, Cancer, and Immunity research unit at the Institut National de la Santé et de La Recherche Médical (INSERM), Director of the Metabolomics and Cell Biology Units at the Gustav Roussy Institute, and Doctor at the Hôpital Européen George Pompidou in Paris.
Dr. Kroemer’s contributions have been recognized with numerous awards. He was elected a member of German Academy of Sciences (Leopoldina) and received the organization's Carus Medal. He was named a fellow of the European Academy of Sciences. He has received the Léopold Griffuel Prize of the French Association for Cancer Research an Advanced Investigator Award from the European Research Council, the Mitjavile Prize of the French Academy of Medicine, the Galien Prize for Pharmacological Resarch, the Grand Prix Claude Bernard of the City of Paris (2, the Brupbacher Prize for Cancer Research, the ADPS Longevity Research Award, the Baillet-Latour Health Prize and the international Lombardia è Ricerca Prize among others.
Guido Kroemer currently serves on the Editorial Boards of Cell Death & Differentiation, Cell Research, EMBO Journal, EMBO Molecular Medicine, Molecular & Cellular Biology, and Science Signaling. Kroemer is also the Editor-in-Chief of four journals, Cell Stress, OncoImmunology, Microbial Cell, and Molecular & Cellular Oncology. He is member of the European Molecular Biology Organization (EMBO), Austrian Academy of Sciences, Academia Europaea, European Academy of Sciences (EAS), European Academy of Sciences and Arts (EASA), European Academy of Cancer Sciences (EACS), and Institut Universitaire de France (IUF). He is the Director of the Paris Alliance of Cancer Research Institutes (PACRI), the Founding Director of the European Research Institute for Integrated Cellular Pathology (ERI-ICP), and the Founding President of the European Academy of Tumor Immunology (EATI).
Scientific Advisory Board
Thomas Pieber, PhD
Dr. Pieber is the author of more than 400 scientific publications. His research focus is on endocrinology, diabetes and metabolism, obesity regenerative medicine, medical device development, nanomedicine, and nanotoxicology.
Dr. Pieber is Head of the University Clinic for Internal Medicine and Head of the Clinical Department for Endocrinology and Diabetology at the Medical University of Graz, Austria. He is Director of the HEALTH Institute – Institute for Biomedicine and Health Sciences of the Joanneum Research Forschungsgellschaft mbH in Graz.
Dr. Pieber’s group developed a novel technique called open-flow microperfusion (OFM) which is used to explore energy metabolism in adipose and muscle tissue in diabetes. His research has also addressed the role of 15-hydroxy-vitamin D in immune tolerance and autoimmunity. In a joint research effort with leading obesity centers in Europe, his group addresses the role of immune competent cells and novel pathways of chronic inflammation in obesity and diabetes.
He serves as Chief Scientific Officer at CBmed GmbH, which links excellent research infrastructure, scientific expertise, medical knowledge, national and international industry partners for systematic medical biomarker research. Dr. Pieber was a post-doctoral researcher in the Department of Internal Medicine at University of Texas Southwest Medical Center.
Scientific Advisory Board
Professor Frank Madeo
One of the most-cited scientists in the field of autophagy, Dr. Frank Madeo discovered the effects of spermidine as an autophagy trigger and age-protective substance. Madeo’s research on longevity-promoting, well-tolerated compounds spans various model organisms, including humans. His discovery of the role of spermidine in autophagy induction, cell protection and longevity has pioneered a new and fast-growing area of research and product development, including Longevity Labs’ introduction of its spermidineLIFE® dietary supplement.
Dr. Madeo is Director of the Institute for Molecular Biosciences at the Karl-Franzens University in Graz, Austria. Madeo’s research team works to understand mechanisms of aging to develop new treatment approaches for age-related diseases and extend the healthy lifespan. Dr. Madeo also researches cell death models, the role of the mitochondria in the origination of neurodegenerative diseases, plant-based substances for Parkinson’s disease, and beta-amyloid toxicity in models of Alzheimer’s disease.
Dr. Madeo is a member of the American Academy of Microbiology and founder and editor-in-chief of the journal Microbial Cell. He was awarded the Seneca Medal for Aging Research and is a member of the American Academy of Microbiology.